Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprost.
Stents eluting anti-proliferative drugs limit restenosis, but drugs commonly used to date are relatively non-specific cytostatic agents which inhibit proliferation of intimal endothelial cells as well as medial smooth muscle cells and may thereby contribute to the clinical complications associated with angioplasty. In an effort to identify a more specific anti-proliferative agent, we compared the effects of rapamycin to those of cicaprost, a mimetic of the naturally occurring anti-mitogen, PGI(2). Rapamycin and cicaprost were both strongly anti-mitogenic in vascular smooth muscle cells (VSMCs). But unlike rapamycin, cicaprost did not inhibit mitogenesis in aortic endothelial cells even when used at concentrations >10-fold higher than its ED(50) for VSMCs. Similarly, both rapamycin and cicaprost have been reported to regulate levels of the cdk inhibitor, p27(kip1). But rapamycin remained anti-mitogenic in p27(kip1)-null VSMCs whereas the anti-mitogenic effect of cicaprost was completely dependent on p27(kip1). We conclude that stable PGI(2) mimetics may be highly specific inhibitors of p27(kip1)-dependent VSMC proliferation after vascular injury.
Castagnino
Paola
P
Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6084, United States. pcastagn@mail.med.upenn.edu
Kothapalli
Devashish
D
Hawthorne
Elizabeth A
EA
Xu
Tina
T
Assoian
Richard K
RK
D000818:Animals; D002453:Cell Cycle / Q000187:drug effects*; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D049109:Cell Proliferation; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008938:Mitosis / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D020123:Sirolimus / Q000494:pharmacology
D018797:Cell Cycle Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27; D011464:Epoprostenol; C043867:cicaprost; D020123:Sirolimus
Prostaglandins. 1991 Feb;41(2):97-110
1708156
Annu Rev Med. 2004;55:169-78
14746515
J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91
17174201
Prostaglandins. 1994 Feb;47(2):151-68
8016385
Semin Interv Cardiol. 1996 Sep;1(3):181-4
9552509
Genes Dev. 1999 Jun 15;13(12):1501-12
10385618
Methods Enzymol. 2007;426:155-75
17697884
Lancet. 2004 Oct 23-29;364(9444):1519-21
15500897
Atherosclerosis. 2006 Dec;189(2):288-96
16455087
N Engl J Med. 2003 Oct 2;349(14):1307-9
14523135
Mol Cell Biol. 1996 Dec;16(12):6744-51
8943329
Nat Rev Mol Cell Biol. 2009 May;10(5):307-18
19339977
Nat Med. 1997 Aug;3(8):900-3
9256282
Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):109-18
17164138
Circulation. 2001 Aug 21;104(8):852-5
11514367
J Cardiovasc Pharmacol. 2006 Dec;48(6):286-92
17204907
Cardiovasc Res. 2001 Dec;52(3):500-8
11738067
Science. 1995 Jan 27;267(5197):518-22
7824950
J Biol Chem. 2004 Jul 9;279(28):29109-13
15126498
Science. 2002 Apr 19;296(5567):539-41
11964481
Cardiovasc Res. 2005 Dec 1;68(3):483-92
16111664
Mol Pharmacol. 2006 Nov;70(5):1700-7
16885208
Physiol Rev. 1999 Oct;79(4):1193-226
10508233
Mol Pharmacol. 2003 Aug;64(2):249-58
12869629
Circulation. 1997 Sep 16;96(6):1717-9
9323050